ACXP — Acurx Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $32.62m
- $25.14m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.93 | 4.6 | 12.7 | 12.1 | 14.6 |
Operating Profit | -5.93 | -4.6 | -12.7 | -12.1 | -14.6 |
Net Income Before Taxes | -5.93 | -4.6 | -12.7 | -12.1 | -14.6 |
Net Income After Taxes | -5.93 | -4.6 | -12.7 | -12.1 | -14.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.93 | -4.6 | -12.7 | -12.1 | -14.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.93 | -4.6 | -12.7 | -12.1 | -14.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.622 | -0.482 | -1.5 | -1.12 | -1.15 |
Dividends per Share |